182 related articles for article (PubMed ID: 37676267)
1. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
Kang Y; Zhen H; Ma N; Zhao H; Cao B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
[TBL] [Abstract][Full Text] [Related]
2. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
3. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
[TBL] [Abstract][Full Text] [Related]
4. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A
Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review.
Zafar Z; Vogler C; Hudali T; Bhattarai M
Clin Med Res; 2019 Jun; 17(1-2):29-33. PubMed ID: 31160476
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.
Wang J; Zheng Q; Chen J
Immunotherapy; 2023 Apr; 15(6):409-416. PubMed ID: 36950965
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review.
Palmieri VE; Roviello G; Catalano M; D'Angelo A; Vannini G; Buttitta E; Mini E
Immunotherapy; 2022 May; 14(7):505-510. PubMed ID: 35380054
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report.
Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D
Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941
[TBL] [Abstract][Full Text] [Related]
10. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report.
Taillefer VT; Pigeon M; Chen M; Larochelle C; Florescu M; Bélanger K; Adam JP
J Oncol Pharm Pract; 2020 Sep; 26(6):1538-1543. PubMed ID: 32063105
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced seronegative encephalitis.
Cabral G; Ladeira F; Gil N
J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
[TBL] [Abstract][Full Text] [Related]
16. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
[TBL] [Abstract][Full Text] [Related]
17. A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis.
Takebayashi Y; Neshige S; Hayashi T; Aoki S; Ueno H; Iida K; Maruyama H
Epileptic Disord; 2021 Oct; 23(5):733-738. PubMed ID: 34519645
[TBL] [Abstract][Full Text] [Related]
18. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
